Psoriasis: Clinical Trials

259 trials for Psoriasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

259 completed. 259 Phase 2, 21 Phase 1, 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2259Completed 259
Phase 121Completed 21
Phase 39Completed 9

Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis

Trials (filtered) newest first · largest first

All 259 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of HB0017 in Psoriasis Patients
HB0017 - Psoriasis (PsO)
Phase 2CompletedHuabo Biopharm Co., Ltd.2062024-09-302026-10-23
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
AX-158, Placebo - Psoriasis, Plaque Psoriasis
Phase 1 / Phase 2CompletedArtax Biopharma Inc312023-11-302025-10-03
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
SAR441566, Placebo - Psoriasis
Phase 2CompletedSanofi2212023-10-262025-11-10
To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis
AK111 - Psoriasis, Skin Diseases
Phase 2CompletedAkeso4542023-09-222025-01-23
A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
regular treatment, Intensive treatment - Psoriasis
Phase 2CompletedInnovent Biologics (Suzhou) Co. Ltd.1522023-08-282025-04-27
Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).
HRO350, Placebo - Psoriasis
Phase 2CompletedArctic Bioscience5212023-05-252025-03-25
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
BMS-986322, Placebo - Psoriasis
Phase 2CompletedBristol-Myers Squibb1092023-04-032025-11-25
Chinese Medicine for Patients With Psoriasis
Inflammatory skin disease formula, Placebo - Psoriasis
Phase 2CompletedChinese University of Hong Kong602023-03-202026-07-27
Roflumilast Versus Methotrexate in Psoriasis
Roflumilast, Methotrexate - Psoriasis
Phase 2 / Phase 3CompletedCairo University302023-01-092023-05-16
Topical SGX302 for Mild-to-Moderate Psoriasis
Hypericin - Psoriasis, Plaque Psoriasis
Phase 2CompletedSoligenix152022-12-142026-11-17
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Sonelokimab, Placebo, Adalimumab - Arthritis, Psoriatic
Phase 2CompletedMoonLake Immunotherapeutics AG2072022-12-132026-09-10
Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
GN-037, Clobetasol 17-propionate, Placebo - Psoriasis
Phase 2CompletedGEN İlaç ve Sağlık Ürünleri A.Ş.1902022-12-072025-07-16
High Dose Risankizumab for Psoriasis
risankizumab - Psoriasis
Phase 2CompletedOregon Medical Research Center202022-03-012025-10-24
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
NDI-034858, Placebo - Psoriatic Arthritis
Phase 2CompletedTakeda3052022-01-062024-05-31
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
Orismilast modified release tablets, Placebo - Psoriasis, Skin Diseases
Phase 2CompletedUNION therapeutics2022021-12-302024-04-16
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Guselkumab, Golimumab, Placebo - Arthritis, Psoriatic
Phase 2CompletedJanssen Research & Development, LLC912021-10-252026-07-23
Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis
SHR-1314 injection, placebo - Psoriatic Arthritis
Phase 2CompletedSuzhou Suncadia Biopharmaceuticals Co., Ltd.1122021-10-222024-12-12
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
IBI112 dose 2, IBI112 dose 4, IBI112 dose 1 - Psoriasis
Phase 2CompletedInnovent Biologics (Suzhou) Co. Ltd.2502021-09-232024-01-25
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
Orticumab, Placebo - Psoriasis, Inflammation
Phase 2CompletedAbcentra772021-06-302026-05-11
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
AUR101, Placebo - Plaque Psoriasis
Phase 2CompletedAurigene Discovery Technologies Limited1412021-05-042022-12-13

Showing 20 of 259. Sign in to see all of them.

Narrower conditions

Arthritis, Psoriatic (33)  ·  Skin Diseases (15)  ·  Arthritis, Rheumatoid (8)  ·  Arthritis (7)  ·  Plaque, Amyloid (7)  ·  Pruritus (6)  ·  Lymphoma, Follicular (5)  ·  Spondylitis, Ankylosing (5)  ·  Bronchiolitis Obliterans Syndrome (4)  ·  Inflammation (4)  ·  Dermatitis, Atopic (3)  ·  Eczema (3)  ·  Osteoarthritis (3)  ·  Autoimmune Diseases (2)

Broader conditions

Skin Diseases, Papulosquamous (258)  ·  Skin and Connective Tissue Diseases (257)  ·  Skin Diseases (244)  ·  Musculoskeletal Diseases (35)  ·  Bone Diseases (34)  ·  Joint Diseases (34)  ·  Spinal Diseases (34)  ·  Spondylitis (34)  ·  Spondylarthritis (33)  ·  Spondylarthropathies (33)  ·  Arthritis (28)  ·  Immune System Diseases (18)  ·  Pathological Conditions, Signs and Symptoms (18)  ·  Rheumatic Diseases (9)

Interventions

Adalimumab (9)  ·  apremilast (9)  ·  calcipotriene (9)  ·  bimekizumab (7)  ·  secukinumab (7)  ·  risankizumab (6)  ·  Ustekinumab (5)  ·  Etanercept (4)  ·  Methotrexate (4)  ·  Roflumilast (4)  ·  guselkumab (4)  ·  spesolimab (4)  ·  Alefacept (3)  ·  Betamethasone (3)  ·  Calcitriol (3)

Sponsors

Pfizer (11)  ·  Amgen (9)  ·  Boehringer Ingelheim (8)  ·  Novartis Pharmaceuticals (7)  ·  Abbott (6)  ·  Almirall, S.A. (6)  ·  AbbVie (5)  ·  GlaxoSmithKline (5)  ·  UCB Biopharma SRL (5)  ·  University of Medicine and Dentistry of New Jersey (5)  ·  Bausch Health Americas, Inc. (4)  ·  Galderma R&D (4)  ·  Janssen Research & Development, LLC (4)  ·  LEO Pharma (4)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (4)

Countries

United States (139)  ·  Germany (59)  ·  Canada (49)  ·  Poland (35)  ·  United Kingdom (20)  ·  Japan (19)  ·  Hungary (17)  ·  Czechia (16)  ·  Spain (16)  ·  China (14)  ·  Russia (14)  ·  France (12)  ·  Australia (11)  ·  Bulgaria (11)  ·  Denmark (11)

Top investigators

Binu J Alexander, MD (3)  ·  Alice Gottlieb, MD, PhD (2)  ·  Christoph Willers, MD (2)  ·  Christoph Willers, MD, MBA (2)

Results publications

PMID 35544084, PMID 19380660, PMID 30739254, PMID 31667790, PMID 35789257, PMID 35931879, PMID 36178584, PMID 37316690, PMID 37906417, PMID 40194794, PMID 40862624, PMID 41807031, PMID 12622624, PMID 12813013, PMID 12917302, PMID 15009298, PMID 15327535, PMID 15389187, PMID 15872205, PMID 15888152, PMID 16778789, PMID 16895558, PMID 17287478, PMID 17596167, PMID 18283176, PMID 18384439, PMID 19217154, PMID 19466961, PMID 19587341, PMID 19641206, PMID 19811850, PMID 20015525, PMID 20071701, PMID 20103558, PMID 20231202, PMID 20412573, PMID 20655127, PMID 20716226, PMID 20811392, PMID 21206136, PMID 21244768, PMID 21404914, PMID 21504485, PMID 21623773, PMID 21744074, PMID 22025784, PMID 22056790, PMID 22281165, PMID 22413944, PMID 22455413

NIH funding

2016 (9), 2018 (7), 2017 (6), 2014 (4), 2015 (3), 2023 (3), 2005 (2), 2008 (1), 2009 (1), 2019 (1), P60AR047782 (1), R33AR077495 (1), U44AI114473 (1)